Latest Intelligence on Pharmaceuticals and Healthcare in Europe

Published within

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

UK watchdog's guidance knocks kidney cancer drugs

The UK's cost-effectiveness watchdog NICE has delivered another blow to the developers of targeted cancer therapies by recommending against the use of four new kidney cancer drugs in the UK. This recommendation suggests that NICE is likely to look unfavorably on a number of other targeted therapies in development, severely limiting future growth of the targeted cancer therapies market in the UK.

Published By Datamonitor
12 Aug 2008
CommentWire
CommentWire

UK vaccination: coverage falls but the threat remains

Following a fall in MMR coverage after the 1998 Wakefield report linking the triple jab to autism, new research suggests it could be difficult to restore pre-scare vaccine coverage levels, leaving the country open to a potentially serious outbreak of preventable diseases. Parents need access to full clinical data on vaccines so they can make a properly informed decision.

Published By Datamonitor
25 Aug 2004
Expert View
Expert View

UK recommendation for Merck's Simponi but it may struggle to make an impact

The National Institute for Health and Clinical Excellence has recommended Simponi for psoriatic arthritis. Based on this, Datamonitor believes that the drug will gain further positive recommendations in other rheumatology indications. However, while Simponi does have dosing advantages over other approved biologics, it is unlikely to make a huge impact on the UK market.

Published By Datamonitor
18 Mar 2011
CommentWire
CommentWire

UK pharmaceuticals: potential pricing safe haven

With healthcare reform and cost containment initiatives taking hold throughout Europe, the UK is becoming increasingly attractive to the branded pharmaceutical sector. Through price control deregulation the UK government could attract increased investment, but it must be careful to balance the interests of patients with those of the industry.<BR />

Published By Datamonitor
17 Sep 2003
CommentWire
CommentWire

UK pharmaceuticals: NICE move by the government

The new legislation, designed to end concerns that patients are being denied effective treatment because of funding shortages, will also have a major impact on the pharmaceutical industry. In particular, the makers of Alzheimer's Disease, ADHD and schizophrenia drugs are likely to benefit. The move might even have repercussions in the rest of Europe.

Published By Datamonitor
06 Dec 2001
Expert View
Expert View

UK pharma in need of a check-up

The government's Health Select Committee has published a stinging attack on the UK pharmaceutical industry. In a report spanning 126 pages and consisting of 48 conclusions and recommendations, the committee has lambasted the way in which the UK pharmaceutical industry conducts its business and the motives by which it is driven. Datamonitor's Duncan Emerton looks at the details...

Published By Datamonitor
06 Apr 2005
CommentWire
CommentWire

UK mental health: NIMHE to drive treatment

Published By Datamonitor
12 Jul 2001
ResearchWire
ResearchWire

UK hip implants: ceramic-on-ceramic market to remain small

Published By Datamonitor
14 Aug 2001
CommentWire
CommentWire

UK healthcare: NHS changes will have an impact - eventually

The grossly underfunded NHS is finally receiving some help. The additional funds will be used for modernization, financial incentives, paying debts, and increasing staff - all necessary steps to improve patient care. While this budget increase is only the first step in a 20-year program, any rise in NHS funding is good news for staff, patients - and medical device companies.

Published By Datamonitor
19 Apr 2002
CommentWire
CommentWire

UK healthcare: encouraging patient empowerment

Published By Datamonitor
06 Apr 2001

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

No help is available.